Yang He

Yang He

Auto-generated profile, based on publicly available information

Yang He

Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, 130021, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 January 2022 in Brazilian Journal of Psychiatry
Verified
Journal Article
Open access
NJNingning Jia
Ningning Jia
ZLZhijun Li
Zhijun Li
XLXinwei Li
Xinwei Li
MJMengdi Jin
Mengdi Jin
YLYane Liu
Yane Liu
Qiong YuQiong Yu
Qiong Yu
Objective: To gather current evidence on the impact of antipsychotics on long-term mortality in patients with schizophrenia.Methods: We systematically searched for articles in Embase, PubMed, and PsycINFO reporting the long-term mortality (follow-up > 1 year) of patients with schizophrenia who were using any antipsychotics. We then conducted multiple meta-analyses to determine differences in long-term mortality between different types of antipsychotics.Results: We identified 45 articles that provided unadjusted long-term mortality rates, including 46,171 deaths during 2,394,911 person-years. The pooled mortality rate was 9.9 (95%CI = 7.4-12.7) per 1,000 person-years. The unadjusted crude mortality rate of antipsychotic drug users was lower than that of non-users (risk ratio [RR] = 0.546, 95%CI = 0.480-0.621), first-generation antipsychotics caused higher all-cause mortality than second-generation antipsychotics (RR = 1.485, 95%CI = 1.361-1.620), and polypharmacy had better effects than monotherapy on long-term mortality (RR = 0.796, 95%CI = 0.689-0.921). As for the causes of death, heart disease and cardiovascular disease ranked highest among cause-specific mortality (5.6 per 1,000 person-years).Conclusion: Since antipsychotics had a beneficial effect on long-term mortality in schizophrenia, greater precaution should be taken with patients who do not take them. However, since disease severity, comorbidities, and other confounding factors cannot be fully controlled, further research and verification are needed.

27 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
NJNan Jiang
Nan Jiang
ZLZhijun Li
Zhijun Li
BYBo Yang
Bo Yang
MJMengdi Jin
Mengdi Jin
YSYaoyao Sun
Yaoyao Sun
Qiong YuQiong Yu
Qiong Yu
Objective. To compare the difference of inflammatory cytokines and lymphocyte subsets between deceased patients and survivors with COVID‐19. Methods. This retrospective study included 254 confirmed patients from 10 January to 11 March, 2020, at Tongji Hospital of Wuhan, China. Laboratory and immunologic features were collected and analyzed, and the main outcomes focused on inflammatory cytokines and lymphocyte subsets. Results. A trend of markedly higher levels of inflammatory cytokines as well as lower lymphocyte subset levels in deceased patients was observed compared with survivors. ROC curve analyses indicated that inflammatory cytokines and the decrease levels of T cell, Th (helper T cells) cell, Ts (suppressor T cells) cell, B cell, and NK cell along with Th/Ts ratio increase could be used to predict the death of COVID‐19. Multivariate analyses showed that higher levels of IL‐6, IL‐8, and IL‐10 remained significantly correlated with shorter survival time and that the amount of Ts cells was negatively associated with the possibility of death in COVID‐19 patients. In conclusion, SARS‐CoV‐2 would cause lymphopenia and result in decreased lymphocyte subset cells, particularly in Ts cell counts, which further induces hyperinflammatory response and cytokine storm. IL‐6, IL‐8, IL‐10, and Ts cell might be independent predictors for the poor outcome of COVID‐19.